{
  "abstract": "Background Metastatic breast cancer (mBC) is heterogeneous not only clinically but genomically. Beyond 2–3 lines of therapy, many patients lack access to rationally selected investigational therapies. We evaluated whether a prospective, multi-omics assay from obtained tissue could 1) identify actionable alterations with rapid turnaround and 2) channel patients to biomarker-matched clinical trials, while maintaining procedural safety. Methods BEAT-IT was a prospective study in which core biopsies from patients with mBC (primary and metastatic lesions) were evaluated using immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS). Primary endpoint was the proportion of patients bearing actionable alterations and the proportion referred to biomarker-matched trials. Secondary endpoints included turnaround time (TAT) and biopsy-related morbidity. Proportions are reported with Wilson 95% confidence intervals (CIs). Exploratory subgroup comparisons including molecular subtype comparison were planned with chi-square or Fisher's exact tests. Results Among the 157 enrolled participants, the median TAT from biopsy to finalized report was 20 days. Actionable alterations were identified in 49.0% (77/157; 95% CI 41.3–56.8%). Overall, 49 of 157 patients (31.2%; 95% CI 24.5–38.8%) enrolled in at least one therapeutic clinical trial after profiling. A single grade 1 pneumothorax (1/162 biopsied patients, 0.6%) was the only biopsy-related complication. Retrospective annotation using current ESCAT criteria identified a tier I alteration in 20% of patients with tumor-informative DNA results. Conclusions Prospective, biopsy-triggered multi-omics profiling in mBC is feasible, safe, and delivers clinically actionable results within approximately 3 weeks. Our approach identified actionable alterations in approximately half of patients and supported enrollment in therapeutic clinical trials for nearly one-third. Trial registration: This study evaluated a diagnostic/implementation strategy without assignment to a therapeutic intervention; clinical-trial registration was not required.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 9,
  "authors": [
    {
      "name": "Diego F. Chamorro"
    },
    {
      "name": "Evthokia Hobbs"
    },
    {
      "name": "Meghan Karuturi"
    },
    {
      "name": "Elyse Lopez"
    },
    {
      "name": "Lumarie Santiago"
    },
    {
      "name": "Rony Avritscher"
    },
    {
      "name": "Aysegul Sahin"
    },
    {
      "name": "Funda Meric-Bernstam"
    },
    {
      "name": "Bora Lim"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/cvc78m59rfgwa.bib",
  "cited_by": 0,
  "doi": "10.21203/rs.3.rs-10936036/v1",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13742820/?tool=EBI",
  "id": "cvc78m59rfgwa",
  "issns": [
    "2693-5015"
  ],
  "landing_url": "https://europepmc.org/article/PMC/PMC13742820",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Article"
    ],
    [
      "openalex",
      "1306|Cancer Genomics and Diagnostics"
    ]
  ],
  "openalex": "W7221793131",
  "pdf_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13742820/pdf/?tool=EBI",
  "pmcid": "PMC13742820",
  "pmid": "42999490",
  "published": "2026-10-14",
  "publisher": "American Journal Experts",
  "ris": "https://research.draconitic.com/paper/cvc78m59rfgwa.ris",
  "sources": [
    {
      "first_seen": "2026-11-09T15:20:34Z",
      "native_id": "PMC:PMC13742820",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13742820"
    },
    {
      "first_seen": "2026-11-10T12:23:35Z",
      "native_id": "PMC13742820",
      "source": "pmc",
      "url": "https://doi.org/10.21203/rs.3.rs-10936036/v1"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:1306|Cancer Genomics and Diagnostics",
      "subfield": "oncology"
    }
  ],
  "title": "Breast Cancer Evaluation and Targeted Investigational Therapy (BEAT-IT): A Pilot Prospective Tissue-Testing Study for Breast Cancer Clinical Trial Enrollment",
  "title_text": "Breast Cancer Evaluation and Targeted Investigational Therapy (BEAT-IT): A Pilot Prospective Tissue-Testing Study for Breast Cancer Clinical Trial Enrollment",
  "type": "preprint",
  "updated_at": "2026-11-10T12:23:35Z",
  "url": "https://research.draconitic.com/paper/cvc78m59rfgwa",
  "venue": "Research Square",
  "versions": []
}